Hello and welcome to the latest edition of the Beghou Biopharma Review by Marc Iskowitz.
Can this year’s mega-deals between large drugmakers and big AI players go beyond R&D to help pharma make fuller use of advanced analytics on the commercial side of their business? Meanwhile, a medical strategist shares her keys for turning strong clinical evidence into real-world clinician engagement, and a prescription for dealing with pharma’s vanishing launch window includes a call to start launch prep alongside clinical development — all in this edition of the Beghou Biopharma Review.
AI behemoths to help pharma test potential of agentic in commercial ops
Last week’s BMS-Anthropic deal marked the latest collaboration between a big pharma company and an AI behemoth. Trailing closely behind it were Merck/Google Cloud in March and Novo Nordisk/OpenAI in February.
While all three deals were nominally centered on harnessing AI for drug development, they go beyond R&D to other functions including commercial ops. Pairing directly with AI’s power brokers could set drugmakers up well to implement agentic AI across their product lifecycle.
The takeaway: There’s a lot riding on pharma’s ability to modernize commercial operations, from navigating patent-cliff pressure to preparing for regulatory shifts that are compressing the launch window and moving commercial readiness earlier (see below). That suggests this trend is more than AI-boom FOMO.
What to do now:
- Build governed semantic and retrieval layers that give systems the commercial context needed to generate compliant, actionable insights.
- Start with workflow handoffs where work breaks down, like medical insights to content planning or access barriers to account action.
- Tie AI investments to measurable commercial outcomes — not just to broad ones like launch readiness but to those that are high-friction and cross-functional.
Agreements on paper won’t necessarily give firms an edge, but embedding the technology effectively across commercial ops will. 👀Read my piece here.
3 takes from an HCP-engagement whisperer
Audrey Carnevale of Averitas Pharma — our latest guest on The Space Life Sciences Podcast — shared a thoughtful perspective on how medical teams can turn strong clinical evidence into real-world clinician engagement, cross-functional alignment, and ultimately greater confidence in patient care decisions.
1. Clinical evidence alone doesn’t become engagement
It’s only the starting point. HCPs need to understand where a therapy fits in practice, which patients are most appropriate, and how the data applies in real-world settings.
2. Beware: misalignment that manifests as repetition
Publications, congress activity, MSL conversations, digital content, and commercial messaging may be saying true things, but they should all be building the same clinical conviction, as well.
3. Don’t flood clinicians with information. Build conviction progressively
Sequence evidence by the decision the clinician is trying to make, not by what the brand team wants to communicate next.
🎧 Listen to the podcast here.
Pharma's vanishing launch window — and what to do about it
As discussed above, pharma is facing a rapidly shrinking launch window as regulators increasingly embrace streamlined approval pathways, including single-arm and pivotal trials that compress the timeline between clinical proof and commercialization. As Beghou’s Rohit Gupta asserts in Healthcare Business Today, the first credible dataset is increasingly becoming the launch dataset, forcing companies to align clinical, regulatory, and commercial planning much earlier in development.
That shift raises the stakes for trial design, payer strategy, field-force readiness, and market access planning. Companies can no longer treat commercialization as a post-approval exercise; instead, launch preparation must begin alongside clinical development.
Rohit also notes that as AI-enabled continuous trials and faster review cycles gain traction, pharma organizations with integrated clinical and commercial systems will be best positioned to respond quickly and capture market opportunity.
🧐Check out Rohit’s piece here.
What's next...
Our upcoming webinar, “When your data stack hits a wall” on June 10 at 11 AM ET, is designed for life sciences leaders considering more data investments. Beghou's Adrienne Lovink and Vishal Singal will share a practical framework to identify what's missing from your data stack and how to make sure your investment drives the right outcomes. Register here.
Our Brews with Beghou events are casual happy hours that allow attendees to network with peers from pharma and biotech organizations; connect with Beghou leaders and subject matter experts; and enjoy great drinks, food, and engaging conversation.
- Brews with Beghou North Jersey (June 2 at the Horseshoe Tavern in Morristown) – RSVP here.
- Brews with Beghou Boston (June 3 at Brewer’s Tap) – RSVP here.
That’s it for now. If you’re looking for more context on any of these stories, drop me a line at marc.iskowitz@beghou.com
Thanks for reading,
Marc Iskowitz,
Editorial Director, Beghou